Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CVS · NYSE · Pharmacy & insurance
CVS Health (CVS) · oqro.io/stocks/CVS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Yes. Insiders of CVS Health (CVS) filed 1 open-market purchase in the last 90 days; the latest was filed on Nov 6, 2026.
Since 2006, CVS Health insiders reported 45 open-market purchases and 360 sales on Forms 4 and 5, with purchases in 16 different years, most recently 2026.
No open-market sale by an insider of CVS Health (CVS) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 7 trades in CVS Health (CVS) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Alan Armstrong, Rep. Dwight Evans (PA03), Sen. John Boozman and 1 other member.
CVS Health's next results are expected on Feb 8, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$81.35−4.46 (−5.20%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+4.4% (+$3.41) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $77.94 on Nov 18, 2025 to $81.35 on Nov 18, 2026 (+4.4%). Disclosed in this range: 10 insider trades, 0 pre-arranged insider sales, 4 Congress trades, and 117 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmacies, Aetna insurance and care services.
Last 12 months
+4.4%
Market value
$104B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 17.9M shares sold short (1.4% of shares outstanding), +10.4% vs the previous count, 2.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$108B
+5.4% vs the same quarter a year earlier
Free cash flow, last 12 months
$15.6B
This quarter $3.91B, a year earlier $98M
Net debt
$45.5B
Debt $57.2B, cash $11.7B, at Sep 30, 2026
Net income, last 12 months
$11B
Operating profit covers interest 4.9x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Revenue, fiscal 2025
$402B
+7.8% vs the year before
Net income, fiscal 2025
$1.77B
As reported in the annual filing
Shares outstanding
1.28B
As of Oct 28, 2026
In fiscal 2025 the company spent $3.4B on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
First insider buy since Jun 2025Traded Nov 6 · filed the same day
Since the trade −3.0% · S&P 500 −0.7% · to Nov 18
CVS Health's and Group President paid $2M out of pocket for CVS Health shares. It was the first purchase in over a year. Shares held went up 37% with this purchase.
Federal contracts
Best 3 task order; health care data sources for surveillance of biologics. Eo 14398
The Department of Health and Human Services has committed $6.99M to CVS Health so far. It runs until Sep 29, 2027.
Federal contracts
Pharmacy medication repackaging and dispensing services
The Department of Veterans Affairs has committed $204K to CVS Health so far. It runs until Apr 1, 2027.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for CVS Health over the 12 months to Nov 18, 2026: 1 product recall (10th most among listed companies) and 15 executive contributions.
Top officer leaving
“Gallina served in the CFO role for Elevance from June 2016 through November 1, 2023, then served as EVP and Advisor to the CEO from November 1, 2023 until May 2024, when he retired.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Insiders of CVS Health reported 45 open-market purchases and 360 sales since 2006; purchases in 16 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $2M1×1 trade | $359M9×9 trades |
| 2025 | $2.1M3×3 trades | $255M8×8 trades |
| 2024 | $557K4×4 trades | $2.27M1×1 trade |
| 2023 | $1.12M2×2 trades | $1.93M2×2 trades |
| 2022 | $106K1×1 trade | $71.8M26×26 trades |
| 2021 | $455K2×2 trades | $97.3M23×23 trades |
| 2020 | $316K1×1 trade | $27.4M8×8 trades |
| 2019 | $1.68M6×6 trades | $36.6M8×8 trades |
| 2018 | $2.13M2×2 trades | $8.35M8×8 trades |
| 2017 | — | $104M22×22 trades |
| 2016 | — | $24.2M11×11 trades |
| 2015 | — | $84.4M22×22 trades |
| 2014 | — | $128M31×31 trades |
| 2013 | — | $32.4M20×20 trades |
| 2012 | $2.74M3×3 trades | $91.9M48×48 trades |
| 2011 | $95K3×3 trades | $18.2M14×14 trades |
| 2010 | $6.96M5×5 trades | $89.9M13×13 trades |
| 2009 | $539K3×3 trades | $69M17×17 trades |
| 2008 | $601K3×3 trades | $93M11×11 trades |
| 2007 | $247K4×4 trades | $144M47×47 trades |
| 2006 | $83K2×2 trades | $19.7M11×11 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Fiduciary Duties in Selecting Designated Investment Alternatives
Proposed rule · Employee Benefits Security Administration
United States v. Hewlett Packard Enterprise Co. and Juniper Networks, Inc.; Response of the United States to Public Comments on the Proposed Final Judgments
Notice · Antitrust Division
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Against the S&P 500 over the year
Since Nov 14, 2025, CVS is up 10.3% and the index fund is up 9.0%: 1 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CVS moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
A securities lawsuit naming the company as a defendant was filed on Mar 11, 2025 in the Court of Appeals for the First Circuit. A filing is an allegation, not a finding.
In Re: CVS Health Corp. Securities Act Litigation, 25-1230A securities lawsuit naming the company as a defendant was filed on Jul 12, 2024 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
Nixon v. CVS Health Corporation, 1:24-cv-05303Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). 1 case in that period is closed and not listed. Coverage of court records is not complete, and shareholder derivative suits are not included.
1 notice filed with state agencies, covering 53 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
Short sale volume: 26.0% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 38.1%. FINRA daily files, to Nov 18, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 8, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
83%
19 of 23 insider purchases since 2018 came within 30 days after a results announcement
From CVS Health's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know CVS Health's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.